Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Clinical trial NCT05422365 · COMPLETED
Trial details
- NCT number
- NCT05422365
- Sponsor
- Biopharma Plasma LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-26
- Primary completion
- 2023-12-14
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.